Levin Capital Strategies, L.P. Summit Therapeutics Inc. Transaction History
Levin Capital Strategies, L.P.
- $1.03 Billion
- Q3 2024
A detailed history of Levin Capital Strategies, L.P. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Levin Capital Strategies, L.P. holds 36,176 shares of SMMT stock, worth $658,764. This represents 0.08% of its overall portfolio holdings.
Number of Shares
36,176
Previous 39,176
7.66%
Holding current value
$658,764
Previous $305,000
159.67%
% of portfolio
0.08%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$445 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$199 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$99.1 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$63.2 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.66B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...